Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.

Scientific reports - 6 Apr 2017

Tan Philip K, Liu Sha, Gunic Esmir, Miner Jeffrey N

Abstract excerpt

Gout is caused by elevated serum urate levels, which can be treated using inhibitors of the uric acid transporter, URAT1. Here, we characterize verinurad (RDEA3170), which is currently under evaluation for gout therapy. Verinurad specifically inhibits URAT1 with a potency of 25 nM. High affinity inhibition of uric acid transport requires URAT1 residues Cys-32, Ser-35, Phe-365 and Ile-481. Unlike other available...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Transport
Share to Gout
Share to Hyperuricemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Molecular Targeted Therapy

Share to Organic Anion Transporters

Share to Organic Cation Transport Proteins

Share to Uric Acid

Source

Open in PubMed Open full text

Identifiers

PMID: 28386072
DOI: 10.1038/s41598-017-00706-7
PMCID: PMC5429603

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout.PMID 28386072Read ↗

Molecular mechanisms of uric acid transport by the native human URAT1 and its inhibition by anti-gout drugsSemantic proximity Read ↗

Molecular basis of the urate transporter URAT1 inhibition by gout drugsSemantic proximity Read ↗

ABCG2 as a therapeutic target candidate for gout.Semantic proximity Read ↗

Recent advances in understanding and managing goutSemantic proximity Read ↗

hURAT1 Transgenic Mouse Model for Evaluating Targeted Urate-Lowering Agents.Semantic proximity Read ↗

<i>hURAT1</i> Transgenic Mouse Model for Evaluating Targeted Urate-Lowering AgentsSemantic proximity Read ↗

Equilibrative nucleoside transporters-A review.Semantic proximity Read ↗

Highly Selective Y4 Receptor Antagonist Binds in an Allosteric Binding Pocket.Semantic proximity Read ↗

Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and GoutSemantic proximity Read ↗

Novel Nucleotide Human Immunodeficiency Virus Reverse Transcriptase Inhibitor GS-9148 with a Low Nephrotoxic Potential: Characterization of Renal Transport and AccumulationSemantic proximity Read ↗

Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.Semantic proximity Read ↗

Recent advances in the in silico modelling of UDP glucuronosyltransferase substrates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.